Tarsus Pharmaceuticals Inc.

Tarsus Pharmaceuticals Inc. annual/quarterly operating income history and growth rate from 2020 to 2026. Operating income (EBIT) is profit from core business operations, excluding interest and income taxes. It reflects the efficiency of a company's core operations.

• Tarsus Pharmaceuticals Inc. operating income for the quarter ending March 31, 2026 was -6.1 M, a 76.70% decrease year-over-year.
• Tarsus Pharmaceuticals Inc. operating income for the twelve months ending March 31, 2026 was -69.1 M, a 49.58% decrease year-over-year.
• Tarsus Pharmaceuticals Inc. annual operating income for 2025 was -71.0 M, a 41.14% decrease from 2024.
• Tarsus Pharmaceuticals Inc. annual operating income for 2024 was -120.6 M, a 15.78% decrease from 2023.
• Tarsus Pharmaceuticals Inc. annual operating income for 2023 was -143.2 M, a 128.28% increase from 2022.
• Tarsus Pharmaceuticals Inc. annual operating income for 2022 was -62.7 M.